ANTIDEPRESSANT-LIKE EFFECTS INDUCED BY GALANIN 2 /NEUROPEPTIDE Y Y1 HETERODIMERS IN THE DENTATE GYRUS OF THE HIPPOCAMPUS

M.Narváez¹, D.O. Borroto-Escuela², C. Millón¹, B. Gago¹, A.Flores-Burgess¹, L. Santín³, K. Fuxe², J.A. Narváez¹ & Z. Díaz-Cabiale¹

1. Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, España
2. Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
3. Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Psicología, Campus de Teatinos s/n, 29071 Málaga, España

Previously, we have described the Galanin (GAL) and Neuropeptide Y Y1 (NPYY1) interactions through GAL receptor 2 and NPYY1 receptor 1 (GALR2/NPYY1R) heterodimers in the Dentate Gyrus (DG) of the Hippocampus, using autoradiographic, in situ hybridization and in situ proximity ligation assay (PLA) (1,2). The current work is to evaluate GALR2 and NPYY1R interactions in relation to depression-like behaviour and c-Fos expression in the Hippocampal DG.

Rats (n=6-8) were forced to swim for a 15-min period (pre-test) and 24 h later were subjected to a 5-min swimming session (test) 15 min after the administration alone or in combination of GAL, the NPYY1R agonist [Leu³¹,Pro³⁴]NPY and the GALR2 antagonist M871. The total duration of immobility, swimming, and climbing periods were scored during the test. For c-Fos immunohistochemistry, experimental groups of rats were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and perfused with 4 % Paraformaldehyde 90 min after icv injections. Then, brains were coronally sliced and immunostained. As primary antibodies, an antibody against c-Fos protein (1:5000, sc- 52, Santa Cruz Biotechnology, CA, USA), revealed with 3,3´-Diaminobenzidine (DAB) plus nickel, was used as an indirect marker of neural activity. The antibody to Calbindin-D28 k (1:1000, Santa Cruz Biotechnology, CA, USA), revealed with DAB, was used to outline the granular region since it marks mainly hippocampal granule cells. Sections were analyzed using the optical fractionator stereological method.

We observed that icv injection of GAL and NPYY1R agonist significantly enhanced the decrease in the immobility (p<0.001) and the increase in the swimming behaviour (p<0.001) compared with the NPYY1R agonist alone. Moreover, a significant enhancement of the decrease in climbing behavior (p<0.05) was also observed. Furthermore, GALR2 is involved in this GALR/NPYY1R interaction, since the presence of the GALR2 antagonist M871 counteracted the enhancement of the decrease in immobility (p<0.01) and in climbing behavior (p<0.05) as well as the
increase in swimming time (p<0.001) induced by the coadministration of GAL and NPYY1R agonist in the FST.

Specific cells populations within DG subregions may be involved in this behavioural effect since the coadministration of GAL and NPYY1 agonist enhances the NPYY1R-mediated reduction (p<0.05) in the number of c-Fos immunoreactive nuclei in the polymorphic region. In this region, the GABA interneurons could be involved in the interaction since c-Fos IR colocalized with a GABAergic marker (GAD65/67) after NPYY1R agonist injection. Moreover, within the granular cells layer, GAL and NPYY1 agonist coadministration significantly increased c-Fos IR expression in the entire granular cell layer compared with GAL (p<0.05) and [Leu31,Pro34]NPY (p<0.01) alone. Again, the co-treatment with the GALR2 antagonist M871 completely reversed the GAL contribution to the responses in both regions, the polymorphic and the granular layer of the DG, demonstrating the involvement of GALR2 in the GAL actions.

These results indicate that GALR2/NPYY1R interactions can provide a novel integrative mechanism in DG in depression-related behavior and may give the basis for the development of drugs targeting GALR2/NPYY1R heteroreceptor complexes in the DG of the hippocampus for the treatment of depression. Study supported by Junta de Andalucia CVI6476 and Proyecto Puente-Universidad de Málaga.
